Actinium Pharmaceuticals (ATNM) on Tuesday shared positive data from the ongoing phase 3 SIERRA study of Iomab-B's single agent effect in patients with...
US stocks were set for an upbeat open Tuesday as markets recover after the tech-heavy Nasdaq Composite index closed nearly 2% lower on Monday on concerns...
Price: 0.30, Change: +0.01, Percent Change: +1.87 ...
Actinium Pharmaceuticals (ATNM) shares were 32% lower Thursday at midday after the biotechnology company priced 42.9 million shares of its common stock and...
| Address | 275 Madison Avenue New York, New York 10016 |
| Phone | +1.646.677.3870 |
| Number of Employees | 30 |
| Recent SEC Filing | 06/07/2019 8-K |
| Executive Chairman & Chief Executive Officer | Sandesh Seth |
| Principal Financial & Accounting Officer | Steve Oloughlin |
| Chief Medical Officer | Mark S. Berger |
| Chief Scientific Officer | Dale L. Ludwig |
| Price Open | $0.25 |
| Previous Close | $0.24 |
| 52 Week Range | $0.23 - 0.87 |
| Market Capitalization | $43.7 M |
| Shares Outstanding | 162.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/08/2019 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.20 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -213.70% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
